CureHealth Diagnostics, India’s leading clinical lab focused in women’s health has unveiled new dimensions in early detection of cervical or lower genital malignancies.CureHealth announced a launch of a novel HPV detection technology in India in technical collaboration with IncellDx, a California based medical health technology company developing advanced molecular diagnostic technologies for detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection.
Preventive Healthcare in India is non-existent. CureHealth is established with a vision to promotewomen’s preventive care in the area of lower genital cancers and sexually transmittable infections by enhancing awareness among common public, by working with the clinical fraternity and making state-of-the-modern-care technologies at affordable costs for many.
“Our Mission is to incorporate advanced molecular and cellular diagnostic procedures to improved patient care at affordable prices by many” said Mr. Pankaj Bhatia, Executive Director of CureHealth Diagnostics. “By being a partner reference laboratory of choice for the clinicians to allow accurate disease prognosis, we aim to be the most responsive and personalized patient-oriented service provider laboratory in India”, he added.
In women’s health, most genital infections caused by bacteria or fungal pathogens are easily treatable but for the rising incidence of cervical cancer. Cervical Cancer is caused by human papilloma virus (HPV) as the major causal factors, besides multiparity, multipartners, early age for sex, smoking, oral contraceptives and so forth. It is the most preventable types of cancer but many women are unaware of preventive measures and treatment options that do not require hospitalization. The current methods of disease detection by Pap test, HPV Test or liquid cytology (LBC) are largely deficient owing to issues pertaining to test sensitivity and specificity. The new test named, OncoTect™ being launched by CureHealth Diagnostics for the first time in India utilizes a patient’s original Pap test sample for precisely detecting cervical pre-cancer lesions by identifying the oncogenic activity of HPV in infected cervical cells. Unlike a standard Pap test with a reflex to HPV, HPV OncoTect™ gives patients and gynaecologists correct risk assessment capability.
Dr. Dinesh Gupta, Director of CureHealth Diagnostics opines, “Preventive healthcare in India underlines professional vision and clarity of operations, not to be drifted by situational compulsions. Many clever workers therefore do not attempt to dwell in this area of healthcare at all. Those who continue to find the challenge less rewarding but in the end, have a satisfaction of serving the humanity more meaningfully than being the run-of-the-mill value contributor. In fact, there is no end to this endeavor and hence the progress we initiated years ago through Gentech Diagnostics, must continue…and continue with unending zeal and undiminished spirit because there aren’t too many who have made this a mission of their life!”
Many experts feel that OncoTect HPV Test is “an HPV Test for the Future”.